| Trial name or title |
Field Administration of Stroke Therapy ‐ Magnesium Phase III Trial |
| Methods |
Multicentre, randomised, double‐blind, placebo‐controlled trial |
| Participants |
Patients (both cerebral infarction and intracerebral haemorrhage patients) as identified by the Los Angeles Prehospital Stroke Screen (LAPSS) whose neurological deficits have been present for at least 15 minutes, and who can be treated within 2 hours of symptom onset |
| Interventions |
Magnesium sulphate iv or a matched placebo |
| Outcomes |
Primary outcome: functional outcome at 90 days as measured by the mRS |
| Starting date |
2005 |
| Contact information |
Jeffrey L Saver, Department of Neurology, UCLA Stroke Center, Los Angeles, California |
| Notes |
Funding: National Institute for Neurological Disorders and Stroke, NIH, American Heart Association |
